GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (OTCPK:AAVXF) » Definitions » Short Interest

Abivax (Abivax) Short Interest


View and export this data going back to 2016. Start your Free Trial

What is Abivax Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Abivax's Short Interest

For the Biotechnology subindustry, Abivax's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abivax's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abivax's Short Interest distribution charts can be found below:

* The bar in red indicates where Abivax's Short Interest falls into.


Abivax (Abivax) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (OTCPK:AAVXF) » Definitions » Short Interest
Comparable Companies
XPAR:VLA XPAR:NANO XPAR:DBV XPAR:IPH XPAR:IVA XPAR:AELIS XPAR:MEDCL XPAR:GNFT XPAR:TNG XPAR:ALSEN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ABVX:USA ABVX:France 2X10:Germany
Address
7-11 boulevard Haussmann, Paris, FRA, 75009
Website
https://www.abivax.com
Abivax SA is a France-based biotechnology company. It is focused on using antiviral technology platforms targeting the immune system to eliminate viral diseases. The antiviral and immunotherapeutic products that the group develops result from three technology platforms; a Modulation of RNA Biogenesis platform, an Immune stimulation platform, and a Polyclonal antibody platform. The Antiviral platform targets the formation of Ribonucleoprotein in the nucleus or the cytoplasm of the infected cell during viral infection, the Immune stimulation platform focuses on invariant natural killer agonists and the Polyclonal antibodies platform generates neutralizing antibodies against different viruses. Its current pipeline includes ABX464 for Ulcerative Colitis and ABX196 for Hepatocellular Carcinoma.